Efficacy

Introduction to Tagrisso (Osimertinib)

Tagrisso (osimertinib) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to inhibit both EGFR-sensitizing and EGFR T790M resistance mutations, with activity against central nervous system metastases. Osimertinib has been shown to be effective in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. The efficacy of osimertinib was demonstrated in several clinical trials, including the FLAURA study, which was a phase III clinical trial comparing osimertinib to standard EGFR-TKIs in the first-line treatment of patients with NSCLC harboring EGFR mutations.

Vizimpro (Dacomitinib) Overview

Vizimpro (dacomitinib) is another EGFR inhibitor, but it is a second-generation TKI. It is designed to inhibit the activity of EGFR as well as HER2 and HER4, with additional activity against EGFR exon 19 deletion or exon 21 L858R substitution mutations. The efficacy of dacomitinib was established in the ARCHER 1050 study, a phase III clinical trial comparing dacomitinib to gefitinib in the first-line treatment of patients with NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.

Efficacy of Tagrisso in Lung Cancer

In the landmark FLAURA trial, osimertinib significantly improved progression-free survival (PFS) compared to standard EGFR-TKIs (erlotinib or gefitinib) in previously untreated patients with NSCLC and EGFR mutations. The median PFS for patients treated with osimertinib was 18.9 months, compared to 10.2 months for those receiving standard treatment. Additionally, osimertinib showed a favorable safety profile and was associated with a higher response rate and longer duration of response. It has become a preferred first-line treatment option for patients with advanced NSCLC with EGFR mutations due to its efficacy and tolerability.

Efficacy of Vizimpro in Lung Cancer

In the ARCHER 1050 study, dacomitinib also demonstrated a significant improvement in PFS when compared to gefitinib in the first-line treatment of patients with advanced NSCLC with EGFR mutations. The median PFS for patients receiving dacomitinib was 14.7 months, versus 9.2 months for those on gefitinib. Furthermore, dacomitinib showed an increased overall response rate. However, it is important to note that dacomitinib has a distinct side effect profile that may require careful management. Despite this, for certain patient populations, dacomitinib offers a valuable treatment option.